Table 2.
Distribution of CT-ECV, ΔHU (tumor), and serum biomarkers in colorectal cancer patients with different tumor differentiation.
| Variables | Total (n = 200) | Well-differentiated (G1) (n = 97) | Moderately differentiated (G2) (n = 57) | Poorly differentiated (G3) (n = 46) | χ²/F/H | P-value |
|---|---|---|---|---|---|---|
| CT-ECV (%) | 32.5 ± 6.4 | 29.8 ± 5.2 | 33.5 ± 5.7 | 37.2 ± 6.1 | 22.184 | <.001* |
| ΔHU (tumor) | 48.6 ± 10.5 | 44.7 ± 8.6 | 49.2 ± 9.7 | 54.5 ± 11.0 | 19.673 | <.001* |
| CEA (ng/mL) | 12.3 (5.8–27.6) | 8.5 (3.2–18.7) | 14.9 (7.5–32.1) | 25.4 (12.6–58.7) | 21.457 | <.001* |
| CA19-9 (U/mL) | 35.2 (18.4–79.5) | 26.7 (14.5–52.3) | 39.8 (19.6–85.9) | 56.3 (28.7–110.4) | 17.983 | <.001* |
| CA125 (U/mL) | 21.4 (12.5–46.8) | 16.8 (10.2–34.7) | 24.9 (13.6–57.3) | 37.2 (18.5–69.4) | 13.746 | .001* |
| NLR | 3.2 (2.1–5.4) | 2.6 (1.8–3.9) | 3.5 (2.4–5.8) | 4.8 (3.1–7.3) | 18.629 | <.001* |
| PLR | 176.3 (132.5–235.7) | 154.8 (120.4–198.6) | 182.7 (140.9–245.3) | 223.6 (167.8–290.4) | 16.302 | <.001* |
CA125 = carbohydrate antigen 125, CA19-9 = carbohydrate antigen 19-9, CEA = carcinoembryonic antigen, CT-ECV = CT-derived extracellular volume fraction, NLR = neutrophil-to-lymphocyte ratio, PLR = platelet-to-lymphocyte ratio.